Korea's Hanmi And Merck in Discussion to Sell Hanmi's Hypertension Drug In Other Countries including Six Asia-Pacific Countries
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Hanmi Pharmaceutical and MSD are pushing to sell Hanmi's incrementally modified hypertensive amlodipine product Amosartan in other countries includng six Asia-Pacific countries under Merck's brand Cozzar XQ
You may also be interested in...
Will GSK-Hanmi Deal Trigger Similar Tie-ups With Korean Pharmas?
Korea’s Hanmi Pharmaceutical is positioning itself as a partner of choice for reformulations and fixed-dose combinations after inking its second major deal with a multinational.
Will GSK-Hanmi Deal Trigger Similar Tie-ups With Korean Pharmas?
Korea’s Hanmi Pharmaceutical is positioning itself as a partner of choice for reformulations and fixed-dose combinations after inking its second major deal with a multinational.
Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
SEOUL - Merck & Co. Inc.'s emphasis on lifecycle management for its Cozaar brand is good news for Hanmi Pharmaceutical, as Merck recently expanded a marketing rights deal for Hanmi's ARB/CCB combination that pairs amlodipine with Merck's losartan. A deal that started in 2009 for the Korean market now stands at 30 markets and signs point to an even broader deal in the future